Group 1 - The company held its 16th temporary board meeting on June 30, 2025, with all 9 directors present and voting [1][2] - The board unanimously approved the proposal to amend the company's articles of association and related rules, which will be submitted for shareholder approval [1][2] - The company plans to revise the Independent Director Working System to align with legal requirements and business needs [2][3] Group 2 - The company has scheduled its second temporary shareholder meeting for July 16, 2025, in compliance with legal and regulatory requirements [3] - The decision to hold the shareholder meeting was also unanimously approved by the board [3]

Core Viewpoint - The company, Jiasitang Pharmaceutical Co., Ltd., has revised its Articles of Association to enhance corporate governance and compliance with regulatory requirements [1][2]. Summary by Relevant Sections Corporate Governance - The revision includes the addition of a section on independent directors to clarify their responsibilities and duties [1][2]. - A new chapter on the specialized committees of the board has been introduced to define their roles and responsibilities more clearly [1][2]. Terminology Adjustments - The term "shareholders' meeting" has been changed to "shareholders' assembly" throughout the document [1][2]. Compliance and Regulatory Updates - The revisions align with the Company Law of the People's Republic of China, the Guidelines for Articles of Association of Listed Companies, and the Shenzhen Stock Exchange Listing Rules [1][2]. - Outdated regulatory references have been removed from the Articles [1][2]. Operational Changes - The position of Chief Executive Officer has been removed, and the powers of the President have been refined [1][2]. - New provisions have been added regarding the reporting obligations if a shareholders' assembly cannot be held on time [2]. Future Actions - The proposed amendments will be submitted for approval at the second extraordinary general meeting of shareholders in 2025, after which the company will proceed with the necessary business registration procedures [2].

Core Viewpoint - 嘉事堂药业股份有限公司 is modifying its Independent Director Work System to align with updated legal regulations and business development needs, with the changes requiring approval at the upcoming shareholder meeting [1]. Summary by Sections Modifications to the Independent Director Work System - The company has proposed amendments to 11 articles of the Independent Director Work System [1]. - The specific details of the revisions are not listed in the announcement [1]. - The changes are in accordance with the Company Law (2023 Revision), the Guidelines for Listed Companies (2025 Revision), and the Shenzhen Stock Exchange Listing Rules [1]. Shareholder Involvement - Shareholders holding more than 1% of the company's issued shares can propose candidates for independent directors, subject to election by the shareholders' meeting [1]. - Nominators are prohibited from proposing candidates with whom they have a conflict of interest or other relationships that may affect the independent performance of duties [1]. - Investor protection agencies can publicly request shareholders to delegate their rights to nominate independent directors [1].

Core Points - The company is established as a joint-stock limited company in accordance with the Company Law of the People's Republic of China and other relevant regulations [4][6] - The registered capital of the company is RMB 291.707120 million [4] - The company was approved by the State-owned Assets Supervision and Administration Commission and registered in Beijing [4][6] - The company aims to utilize a sound operating mechanism to promote sustainable development and provide good returns to shareholders [6][7] Chapter Summaries Chapter 1: General Provisions - The company is established to protect the legal rights of shareholders, employees, and creditors [4] - The company was listed on the Shenzhen Stock Exchange on August 18, 2010, with an initial public offering of 40 million shares [4] - The legal representative of the company is the chairman, who is responsible for civil activities conducted in the company's name [5][6] Chapter 2: Business Objectives and Scope - The company's business objective is to promote the modernization and internationalization of the pharmaceutical industry in China [6] - The business scope includes the sale of various pharmaceutical products, medical devices, and food products [7] Chapter 3: Shares - The company issues shares in the form of stocks, with a par value of RMB 1.00 per share [8][9] - The total number of issued shares is 291.707120 million [8] Chapter 4: Party Committee - The company has established a Party Committee to ensure the implementation of national policies and oversee major decisions [14][15] Chapter 5: Shareholders and Shareholders' Meeting - The company maintains a shareholder register based on the records provided by the securities registration and settlement institution [16] - Shareholders have rights to dividends, attend meetings, and supervise the company's operations [16][17] - The company must hold an annual shareholders' meeting within six months after the end of the fiscal year [25][50] Chapter 6: Shareholders' Meeting Procedures - The company must notify shareholders of meetings at least 20 days in advance for annual meetings and 15 days for temporary meetings [62][63] - The meeting must be presided over by the chairman or a designated representative [74] Chapter 7: Voting and Resolutions - Resolutions can be classified as ordinary or special, with different voting thresholds required for approval [82][84] - Ordinary resolutions require a simple majority, while special resolutions require two-thirds of the voting rights [82][84]

Summary of Key Points Core Viewpoint The document outlines the rules and regulations governing the shareholders' meetings of Jiasitang Pharmaceutical Co., Ltd., ensuring the protection of shareholders' rights and the proper functioning of the company in accordance with relevant laws and regulations. Group 1: General Provisions - The rules are established to regulate the behavior of the company and protect the legal rights of shareholders, ensuring efficient and lawful operation of the shareholders' meeting [1][2] - The rules apply to all shareholders, their representatives, and company officials, binding them to adhere to the established guidelines [2][3] - The shareholders' meeting is the power institution of the company, responsible for electing directors, approving financial reports, and making decisions on capital changes and major asset transactions [2][4] Group 2: Shareholders' Meeting Procedures - The company must hold an annual shareholders' meeting within six months after the end of the previous fiscal year [5] - Temporary meetings can be called within two months of certain events, such as insufficient directors or significant losses [6][7] - The company must report to regulatory bodies if it fails to convene a meeting within the specified time [7][8] Group 3: Proposals and Notifications - Shareholders can propose agenda items, which must comply with legal and regulatory requirements [17][18] - The board must notify shareholders of the meeting details at least 20 days in advance for annual meetings and 15 days for temporary meetings [22][23] - Proposals not included in the meeting notice cannot be voted on [10][11] Group 4: Voting and Resolutions - Voting is conducted by registered shareholders, with each share representing one vote [37] - Ordinary resolutions require a simple majority, while special resolutions require two-thirds approval [39][40] - The company must disclose the results of the voting and the details of the resolutions passed [51][52] Group 5: Execution and Information Disclosure - The board is responsible for executing the resolutions made during the shareholders' meeting [52] - Information regarding the meetings and resolutions must be disclosed in accordance with the company's disclosure policies and relevant laws [21][22] - The rules can be amended based on changes in laws or decisions made by the shareholders' meeting [56][57]

嘉事堂药业股份有限公司 董事会议事规则 2025 年 6 月 30 日 （尚需公司 2025 年第二次临时股东大会审议） 嘉事堂药业股份有限公司 目 录 | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 董事会与董事长的职权 | 1 | | 第三章 | 董事会会议制度 | 3 | | 第四章 | 董事会议事程序 | 4 | | 第五章 | 董事会会议的信息披露 | 7 | | 第六章 | 董事会决议案的执行和反馈 | 7 | | 第七章 | 附则 | 8 | 嘉事堂药业股份有限公司 第一章 总则 嘉事堂药业股份有限公司 第一条 为了确保嘉事堂药业股份有限公司（以下简称"公司"）董 事会落实股东会决议，确保董事会做出科学、迅速和谨慎的决策，规范董 事会的议事程序，根据《中华人民共和国公司法》等有关法律、行政法规、 部门规章和《嘉事堂药业股份有限公司章程》（以下简称"《公司章程》"）， 特制定本规则。 第二章 董事会与董事长的职权 第二条 根据《公司章程》的有关规定，董事会行使下列职权： （一）召集股东会，并向股东会报告工作； （二）执行股东会的决议； （三）决定公司的经营 ...

嘉事堂药业股份有限公司 嘉事堂药业股份有限公司 股东会议事规则 2025 年 6 月 30 日 （尚需公司 2025 年第二次临时股东大会审议） 嘉事堂药业股份有限公司 | | | | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 股东会的召集 | 3 | | 第三章 | 股东会的提案与通知 | 5 | | 第四章 | 股东会的登记 | 7 | | 第五章 | 股东会的召开 | 8 | | 第六章 | 提案的审议 | 9 | | 第七章 | 股东会的表决 | 10 | | 第八章 | 股东会的会议记录及会议决议 | 12 | | 第九章 | 股东会决议的执行和信息披露 | 13 | | 第十章 | 附则 | 13 | 嘉事堂药业股份有限公司 第一章 总则 第一条 为规范嘉事堂药业股份有限公司（以下简称"公司"） 行为，维护公司和股东的合法权益，明确股东会的职责和权限，保证 股东会规范、高效、平稳运作及依法行使职权，根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司股东会规则》、《深圳证券交易所股 票 ...

嘉事堂药业股份有限公司公司章程 嘉事堂药业股份有限公司章程 2025 年 6 月 30 日 （尚需公司 2025 年第二次临时股东大会审议） | ਨ | | --- | | 第一章 | 总则 1 | | --- | --- | | 第二章 | 经营宗旨和范围 3 | | 第一节 | 股份发行 3 | | 第二节 | 股份增减和回购 4 | | 第三节 | 股份转让 6 | | 第四章 | 党委 7 | | 第五章 | 股东和股东会 8 | | 第一节 | 股东的一般规定 8 | | 第二节 | 控股股东和实际控制人 11 | | 第三节 | 股东会的一般规定 13 | | 第四节 | 股东会的召集 15 | | 第五节 | 股东会的提案与通知 17 | | 第六节 | 股东会的召开 19 | | 第七节 | 股东会的表决和决议 22 | | 第六章 | 董事和董事会 28 | | 第一节 | 董事的一般规定 28 | | 第二节 | 董事会 32 | | 第三节 | 独立董事 38 | | 第四节 | 董事会专门委员会 42 | | 第七章 | 审计委员会 43 | | 第八章 | 总裁及其他高级管理人员 4 ...

证券代码：002462 证券简称：嘉事堂 公告编号：2025-23 嘉事堂药业股份有限公司 特此公告。 附件：《独立董事工作制度》修订对比说明 嘉事堂药业股份有限公司董事会 嘉事堂药业股份有限公司（以下简称"公司"）2025 年 6 月 30 日召开的第 七届董事会第十六次临时会议审议通过了《关于修改<嘉事堂药业股份有限公司 独立董事工作制度>的议案》，根据《中华人民共和国公司法（2023 修订）》《上市 公司章程指引（2025 修订）》《深圳证券交易所股票上市规则》等相关法律法规 的要求，并结合公司业务发展需要等实际情况，嘉事堂拟对《独立董事工作制度》 （以下简称"《工作制度》"）进行修改。 本次《工作制度》共修改 11 条。主要修改内容为： 1、调整文字表述，将"股东大会"修改为"股东会"，共涉及条款 10 条， 相关修订不再具体列示； 2、将提名独立董事的权利由监事会改为审计委员会，具体修订内容详见附 件。 关于修订《独立董事工作制度》的公告 上述事项尚需提交 2025 年第二次临时股东大会审议通过。 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 附件 ...

证券代码：002462 证券简称：嘉事堂 公告编号：2025-22 嘉事堂药业股份有限公司 关于修订公司《章程》及其附件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 公司 2025 年 6 月 30 日召开的第七届董事会第十六次临时会议审议通过了 关于修改《嘉事堂药业股份有限公司章程》的议案，为进一步规范和优化公司治 理程序，根据《中华人民共和国公司法》《上市公司章程指引》《深圳证券交易 所股票上市规则》等监管规则，结合公司实际情况，现拟对公司《章程》及其附 件予以修订。主要修订内容包括： 1、本次对《公司章程》的修订中，新增 33 条，减少 31 条，修改 152 条。 主要修改内容包括：调整文字表述，将"股东大会"修改为"股东会"；新增独 立董事章节，进一步规范独立董事职责及履职要点；新增董事会专门委员会章节， 进一步明确董事会专门委员会职责及履职要点；根据公司实际情况删除首席执行 官职务，完善总裁职权；删除援引已废止的监管规则的相关条目。具体修改内容 详见附件 1。 2、本次对《公司章程》附件《股东会议事规则》的修订中，新增 2 条，减 少 1 ...